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DObjective: Aortic valve replacement remains the standard treatment for symptomatic severe aortic stenosis.
However, catheter-based approaches have recently emerged as therapeutic options for high-risk surgical candi-
dates. The objective of this study is to use propensity scoring to compare early clinical outcomes after transapical
aortic valve implantation and conventional aortic valve replacement.
Method: Propensity scoring based on logistic regression modeling of 16 preoperative patient characteristics was
used to identify a group of very high-risk patients undergoing isolated conventional aortic valve replacement
comparable to those patients undergoing transapical aortic valve implantation. McNemar’s test was used to com-
pare early clinical outcomes between the 2 treatment groups, including 30-day mortality and in-hospital post-
operative complications.
Results: Ninety-two patients receiving transapical aortic valve implantation between October 2005 and April
2010 met inclusion criteria for this study. Half of these patients were successfully matched 1:1 to a patient re-
ceiving conventional aortic valve replacement. Baseline characteristics were similar between the 2 treatment
groups after propensity matching. There were 4 perioperative deaths (8.7%) in the conventional aortic valve re-
placement group and 6 perioperative deaths (13%) in the transapical aortic valve implantation group (P>.05).
There were no significant differences in the rates of cerebrovascular accidents, wound infections, reoperation for
bleeding, or length of postoperative hospital stay between the 2 groups (P>.05).
Conclusions: Among high-risk propensity-matched patients, early clinical outcomes are similar after transap-
ical aortic valve implantation and conventional aortic valve replacement. However, given the likelihood of re-
sidual selection bias, a prospective randomized trial is necessary to adequately compare the clinical outcomes
after these 2 aortic valve procedures. (J Thorac Cardiovasc Surg 2011;142:e47-52)Aortic valve replacement (AVR) is the treatment of choice
for severe symptomatic aortic stenosis.1 However, less inva-
sive catheter-based approaches, including transarterial and
transapical aortic valve implantation (AVI), have emerged
over the past few years as treatment options for those with
significant comorbidities.2-8 The PARTNER trial recently
demonstrated that in patients with severe aortic stenosis
who were not suitable candidates for surgery, transfemoral
AVI, compared with medical management, significantly
reduced the risk of death from any cause, the composite
end point of death from any cause/repeat hospitalization,
and cardiac symptoms, despite the higher incidence of
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The Journal of Thoracic and CaTransapical AVI is often reserved for individuals with
poor peripheral arterial access, which limits the transarterial
femoral approach.3,6 Initial experience with transapical
AVI, in carefully selected high-risk patients, has been favor-
able with intraoperative mortality of 0% to 2.6%, 30-day
mortality of 4.3% to 23%, and 1-year survival of 71.4%
to 85%.2,3,6-8,10-14 In Vancouver, among our initial 71
patients, overall survivals at 24 and 36 months were
66.3% 6.4% and 58.0% 9.5%, respectively.15 Among
59 patients who survived at least 30 days, 24- and 36-month
survivals were 79.8%  6.4% and 69.8%  10.9%, re-
spectively.15 Despite the promising early results demon-
strated in these case series, it is unclear how postoperative
outcomes, including survival, compare with conventional
AVR, the currently accepted standard of care.
The primary difficulty in comparing clinical outcomes af-
ter these 2 aortic valve procedures is the associated selection
bias. Transapical AVI is currently limited to compassionate
use for individuals at extremely high risk for conventional
surgery, and therefore cannot be compared with all patients
undergoing conventional AVR. The objective of this study
was to use propensity scoring to identify a high-risk popula-
tion of patients undergoing isolated conventional AVRrdiovascular Surgery c Volume 142, Number 2 e47
Abbreviations and Acronyms
AVI ¼ aortic valve implantation
AVR ¼ aortic valve replacement
CVA ¼ cerebrovascular accident
PVD ¼ peripheral vascular disease
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and compare clinical outcomes after the 2 procedures. Spe-
cifically, this study explored 30-day mortality, in-hospital
complications, and length of hospital stay.
MATERIALS AND METHODS
Perioperative data are collected prospectively on all patients undergoing
cardiac surgery in the province of British Columbia and maintained in the
Cardiac Services BC registry. This database was used to identify 2 groups
of patients: (1) patients undergoing transapical AVI and (2) patients under-
going conventional AVR. Conventional AVR cases were performed in 4
hospitals in British Columbia, and transapical AVI cases were performed
in a single center. These 2 groups were then subjected to inclusion and ex-
clusion criteria. Patients were included if they received a primary isolated
aortic valve procedure for severe aortic stenosis between January 2000 and
April 2010. Patients were excluded if they underwent any concomitant car-
diac surgery procedure; had previous aortic valve surgery; received aortic
valve surgery for non-aortic stenosis, such as pure aortic insufficiency, en-
docarditis, aortic root aneurysm, or aortic dissection; underwent surgery
before the year 2000; and had a porcelain aorta. Preoperative baseline char-
acteristics were compared for the 2 treatment groups with the z test for di-
chotomous variables and the unpaired Student t test for continuous
variables.
Propensity scoring was then used to identify a group of very high-risk
patients undergoing conventional AVR comparable to those patients under-
going transapical AVI in an attempt to account for selection bias. The pro-
pensity scoring model was composed of a logistic regression model
including preoperative patient characteristics that demonstrated a statisti-
cally significant imbalance between the 2 treatment groups. This large
number of covariates can be included in the propensity score model be-
cause it is not subject to the limitation of parsimony that characterizes con-
ventional logistic regression modelling. The Greedy algorithm, with
a calliper of 0.001 to 0.1, was then used to match the conventional AVR
cases to the transapical AVI cases 1:1 on the basis of propensity scores.
Transapical AVI cases unable to be matched were excluded from further
analysis. Baseline characteristics were again compared for the 2 groups af-
ter the propensity score-based match using McNemar’s test for dichoto-
mous variables and paired Student t test for continuous variables.
Finally, McNemar’s test was used to compare the dichotomous clinical
outcomes between the 2 treatment groups, including 30-day mortality and
in-hospital postoperative complications. The in-hospital complications of
interest were cerebrovascular accidents (CVAs), wound infections, and re-
operation for bleeding. The Wilcoxon signed-rank test was used to com-
pare length of postoperative hospital stay. The provincial database was
reviewed to determine rates of reoperation for bleeding, and hospital dis-
charge forms were reviewed to determine rates of CVA and wound infec-
tion and length of hospital stay.
RESULTS
Patient Characteristics
From January 2000 to April 2010, 2180 patients meeting
the inclusion and exclusion criteria of this study underwente48 The Journal of Thoracic and Cardiovascular Surgeither conventional AVR (n ¼ 2088) or transapical AVI
(n ¼ 92) for severe aortic stenosis in British Columbia.
Patients undergoing transapical AVI were older (81  12
years vs 69 12 years, P<.0001), with a smaller body sur-
face area and a significantly increased prevalence of comor-
bidities, including pulmonary hypertension, peripheral
vascular disease (PVD), anemia, and renal dysfunction
(Table 1). Patients undergoing transapical AVI were also
more likely to be female (63% vs 44% female, P<.0001).
Sixteen preoperative variables were included in the pro-
pensity score logistic regression model (Table 2). Several
measured preoperative risk factors were not used in the
model because they were not independently associated
with the decision to perform transapical AVI. Excluded
variables included history of malignancy, hypertension, di-
abetes, and known liver disease. On the basis of this pro-
pensity model, 46 of the 92 patients receiving transapical
AVI were successfully matched to a patient receiving con-
ventional AVR. After matching, there were no significant
differences in any of the preoperative variables between
the transapical AVI and the conventional AVR groups, in-
cluding those variables not used in the logistic regression
model (Table 3).
Patients undergoing transapical AVI who were unable to
be matched to the conventional AVR group were signifi-
cantly different from those patients who were matched
(Table 4). Unmatched patients were older (83  5 years
vs 78  8 years, P<.001), with an increased prevalence
of pulmonary hypertension, PVD, anemia, and renal dys-
function (P<.001) compared with the matched patients un-
dergoing transapical AVI. Similarly, there were significant
differences between matched and unmatched patients un-
dergoing conventional AVR (Table 5).
Clinical Outcomes: Propensity-Matched Groups
Within the conventional AVR group, there were 4 perio-
perative deaths, whereas there were 6 perioperative deaths
among the transapical AVI group (Table 6). According to
McNemar’s test, there was no significant difference be-
tween the two 30-day mortality rates (P ¼ .53). Among
the 6 perioperative deaths in the transapical AVI group, 3
occurred among the first 15 cases performed at our center.
The causes of the mortality in the transapical AVI cases
are listed in Table 7. One patient experienced a cardiac ar-
rest before valve insertion and died intraoperatively despite
emergency femoral-femoral cardiopulmonary bypass.
Similarly, there were no significant differences in the
rates of in-hospital complications, including CVA, wound
infection, and reoperation for bleeding (Table 6). There
were no perioperative CVAs or wound infections observed
among the matched transapical AVI cases. Finally, there
was no significant difference in the length of stay in hospital
between the matched transapical AVI group and the
matched conventional AVR group.ery c August 2011
TABLE 1. Baseline characteristics for all transapical aortic valve
implantations and conventional aortic valve replacements
TAVI (n ¼ 92) AVR (n ¼ 2088) P value
Year of surgery 2005–2010 2000–2009
Age (y) 81 (12) 69 (12) <.0001
Male 34 (37%) 1179 (56%) .0001
BSA 1.72 (0.21) 1.92 (0.26) <.0001
NYHA III/IV 88 (96%) 864 (41%) <.0001
CCS III/IV 37 (40%) 403 (19%) <.0001
LVEF<35% 6 (7%) 117 (6%) .354
HTN 85 (92%) 1359 (65%) <.0001
PHTN 69 (75%) 302 (14%) <.0001
Dyslipidemia 75 (82%) 985 (47%) <.0001
PVD 68 (74%) 217 (10%) <.0001
Arrhythmia 49 (53%) 277 (13%) <.0001
COPD 47 (51%) 407 (19%) <.0001
CVA 29 (32%) 407 (19%) <.0001
Renal dysfunction 52 (57%) 310 (15%) <.0001
Diabetes 31 (34%) 404 (19%) .0004
Liver disease 18 (20%) 163 (8%) <.0001
Malignancy 21 (23%) 301 (14%) .0130
Anemia 65 (71%) 231 (12%) <.0001
PCI 32 (35%) 121 (6%) <.0001
MI 51 (55%) 205 (10%) <.0001
GI bleed 19 (21%) 146 (7%) <.0001
Remote smoker 56 (61%) 549 (26%) <.0001
Current smoker 4 (4%) 158 (8%) .875
Previous sternotomy 41 (45%) 113 (5%) <.0001
Creatinine 124 (79) 94 (55) .0006
Hemoglobin 119 (14) 134 (16) <.0001
Values expressed as mean (standard deviation) or number (%). BSA, Body surface
area; CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary
disease; CVA, cerebrovascular accident; GI, gastrointestinal; HTN, hypertension;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New
York Heart Association classification; PCI, percutaneous coronary intervention;
PHTN, pulmonary hypertension; PVD, peripheral vascular disease.
TABLE 2. Maximum likelihood estimates for propensity logistic
regression model
Parameter df Estimate SE P>c2
Intercept 1 10.7952 2.8984 .0002
Age (10 y) 1 1.1619 0.2771 <.0001
Sex 1 1.0509 0.4491 .0193
BSA 1 3.3287 0.9344 .0004
NYHA III/IV 1 1.5298 0.5883 .0093
LVEF<35% 1 1.6551 0.7246 .0224
Previous sternotomy 1 1.3357 0.4539 .0033
Prior CABG 1 2.1248 0.4277 <.0001
PHTN 1 1.2348 0.3832 .0013
Arrhythmia 1 0.1031 0.3898 .7914
PVD 1 1.653 0.3691 <.0001
COPD 1 0.7196 0.3722 .0532
CVA 1 0.1805 0.4285 .6736
Renal dysfunction 1 0.1168 0.391 .7652
GI bleed 1 0.00075 0.4837 .9988
Anemia 1 1.7853 0.3844 <.0001
Smoker 1 1.4905 0.3831 <.0001
SE, Standard error; BSA, body surface area; CABG, coronary artery bypass grafting;
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident;
PHTN, pulmonary hypertension; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association classification; PVD, peripheral vascular disease; GI,
gastrointestinal.
Higgins et al Acquired Cardiovascular Disease
A
C
DClinical Outcomes: Unmatched Groups
Relative to the matched transapical AVI group, the inci-
dence of reoperation for bleeding was significantly higher
in the unmatched group (11% vs 15%, P<.001) (Table
8). However, perioperative mortality seemed to be higher
in the matched transapical AVI group (13%) compared
with the unmatched group (11%), although this difference
was not statistically significant (P ¼ .064) (Table 8). Re-
view of the conventional AVR cases demonstrated an in-
creased rate of 30-day mortality (9% vs 2%, P< .001)
and a trend toward an increased incidence of CVA (4% vs
1%, P ¼ .080) among matched AVR cases compared
with unmatched cases (Table 9).DISCUSSION
The demand for minimally invasive approaches to surgi-
cal procedures continues to increase. Over the past few
years, there has been a significant expansion in the use of
catheter-based approaches to manage aortic valve disease.The Journal of Thoracic and CaThese techniques are currently reserved for compassionate
use among very high-risk patients, but there is considerable
interest in broadening the selection criteria to include indi-
viduals who would be expected to have excellent clinical
outcomes with conventional AVR. However, before these
catheter-based approaches can be routinely offered to low
to moderate risk or young patients, it is imperative to com-
pare the clinical outcomes after these less invasive proce-
dures with the outcomes achievable with the currently
accepted standard of care, conventional AVR.
In comparing morbidity and mortality after transapical
AVI and conventional AVR, selection bias must be ad-
dressed. Walther and colleagues13 recently used propensity
scoring based on 21 preoperative variables to match 100%
of 100 consecutive patients undergoing transapical AVI.
However, their matching technique was inadequately de-
scribed in their article. Furthermore, the successful match
of all patients undergoing transapical AVI raises concerns
about their selection process for transapical AVI cases and
whether patients receiving this new procedure are truly
any different from those receiving conventional AVR. In
our study, we have clearly demonstrated that there are
significant differences between the 2 treatment groups
(Table 1), as would be expected given the current indica-
tions for transapical AVI.
The objective of our study was to be transparent about our
matching process to accurately compare clinical outcomes
between these 2 treatment groups. Despite the documented
selection bias, we were able to match half of the transapical
AVI cases meeting our inclusion and exclusion criteria tordiovascular Surgery c Volume 142, Number 2 e49
TABLE 4. Preoperative characteristics for matched and unmatched
transapical aortic valve implantation cases
Matched TAVI
(n ¼ 46)
Unmatched TAVI
(n ¼ 46) P value
Year of surgery 2005–2010 2006–2010
Age (y) 78 (8) 83 (5) <.001
Male 20 (43%) 14 (34%) .371
BSA 1.75 (0.23) 1.69 (0.19) .173
NYHA III/IV 42 (91%) 46 (100%) .034
CCS III/IV 15 (33%) 22 (48%) .139
LVEF<35% 3 (7%) 3 (7%) 1.000
HTN 40 (87%) 45 (98%) .046
PHTN 26 (57%) 43 (93%) <.001
Dyslipidemia 36 (78%) 39 (85%) .387
PVD 27 (58%) 41 (89%) <.001
Arrhythmia 21 (46%) 28 (60%) .178
COPD 20 (43%) 27 (59%) .124
CVA 13 (28%) 16 (35%) .470
Renal dysfunction 18 (39%) 34 (74%) <.001
Diabetes 17 (37%) 14 (30%) .478
Liver disease 10 (22%) 8 (17%) .546
Malignancy 7 (15%) 14 (30%) .087
Anemia 25 (54%) 40 (87%) <.001
PCI 13 (28%) 19 (41%) .191
MI 22 (48%) 29 (63%) .148
GI bleed 8 (17%) 11 (23%) .477
Remote smoker 23 (50%) 33 (71%) .039
Current smoker 3 (7%) 1 (2%) .240
Previous Sternotomy 17 (37%) 24 (52%) .148
Creatinine 122 (87) 126 (70) .809
Hemoglobin 121 (15) 116 (13) .091
Values expressed as mean (standard deviation) or number (%). TAVI, Transapical
aortic valve implantation; BSA, body surface area; CCS, Canadian Cardiovascular
Society; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular
accident;HTN, hypertension; LVEF, left ventricular ejection fraction;MI,myocardial
infarction; NYHA, New York Heart Association classification; PCI, percutaneous
coronary intervention; PHTN, pulmonary hypertension; PVD, peripheral vascular
disease; GI, gastrointestinal.
TABLE 3. Baseline characteristics for propensity-matched transapical
aortic valve implantation and conventional aortic valve replacement
cases
TAVI (n ¼ 46) AVR (n ¼ 46) P value
Year of surgery 2005–2010 2001–2009
Age (y) 78 (8) 78 (6) .996
Male 20 (0.43) 19 (0.41) .700
BSA 1.75 (0.23) 1.72 (0.24) .928
NYHA III/IV 42 (91%) 43 (93%) 1.000
CCS III/IV 15 (33%) 16 (35%) 1.000
LVEF<35% 3 (7%) 6 (13%) .683
HTN 40 (87%) 38 (83%) .789
PHTN 26 (57%) 29 (63%) .689
Dyslipidemia 36 (78%) 32 (69%) .522
PVD 27 (58%) 25 (54%) .819
Arrhythmia 21 (46%) 18 (39%) .628
COPD 20 (43%) 18 (39%) .838
CVA 13 (28%) 15 (33%) .814
Renal dysfunction 18 (39%) 19 (41%) 1.000
Diabetes 17 (37%) 14 (30%) .677
Liver disease 10 (22%) 5 (11%) .267
Malignancy 7 (15%) 5 (11%) .752
Anemia 25 (54%) 31 (67%) .269
PCI 13 (28%) 11 (24%) .789
MI 22 (48%) 19 (41%) .689
GI bleed 8 (17%) 8 (17%) .803
Remote smoker 23 (50%) 19 (41%) .453
Current smoker 3 (7%) 3 (7%) .683
Previous sternotomy 17 (37%) 17 (37%) .831
Creatinine 122 (87) 118 (105) .982
Hemoglobin 121 (15) 116 (15) .844
Values expressed as mean (standard deviation) or number (%). TAVI, Transapical aor-
tic valve implantation; AVR, aortic valve replacement; BSA, body surface area; CCS,
Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary disease;
CVA, cerebrovascular accident; HTN, hypertension; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; NYHA, New York Heart Association classifica-
tion; PCI, percutaneous coronary intervention; PHTN, pulmonary hypertension;
PVD, peripheral vascular disease; GI, gastrointestinal.
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model that included 16 preoperative characteristics. After
the match, there were no significant differences between
the 2 patient samples included in the analysis. However,
there were significant differences between those patients in-
cluded in the match and those who could not be matched.
Essentially, the lower risk transapical AVI cases were pro-
pensity matched to the highest risk conventional AVR cases.
Therefore, it is imperative that the results of this study
should not be extrapolated to the entire transapical AVI pop-
ulation. Conversely, this study does help illuminate the pro-
cedural risks for high-risk patients who may be considered
for both conventional AVR and transapical AVI.
Currently at out center, patients must be turned down for
conventional AVR by cardiac surgeons before they can be
considered for transapical AVI. However, not all referred
patients are accepted for transapical AVI. Appropriate can-
didates would have a life expectancy of at least 1 year, as
well as a reasonable quality of life, if not for their aortice50 The Journal of Thoracic and Cardiovascular Surgvalve disease. Generally speaking, transapical AVI is not of-
fered to patients with purely rheumatic aortic stenosis, pure
aortic insufficiency, endocarditis or active infection, or
severe mitral stenosis. Furthermore, patients with uncor-
rectable, severe 3-vessel coronary artery disease may not
tolerate rapid ventricular pacing during the procedure.
Between the 2 matched groups in this study, there was
a trend toward increased 30-day mortality in the transapical
AVI group, although this was not statistically significant.
However, when analyzing this outcome, it is important to
consider that transapical AVI is an emerging approach
with limited experience, whereas conventional AVR is
a well-established operation. As we have previously dem-
onstrated, there is a significant learning curve associated
with the new, evolving transapical procedure.14 Our center
was the first in the world to perform transapical AVI and
thus was not mentored by world experts. The 30-day mor-
tality rate among our first 15 transapical cases was 33%
and significantly decreased to 13% in subsequent cases,14ery c August 2011
TABLE 5. Preoperative characteristics for matched and unmatched
conventional aortic valve replacement cases
Matched AVR
(n ¼ 46)
Unmatched AVR
(n ¼ 2042) P value
Year of surgery 2001–2009 2001–2009
Age (y) 78 (6) 69 (12) <.001
Male 19 (41%) 1160 (57%) .030
BSA 1.72 (0.24) 1.92 (0.26 <.001
NYHA III/IV 43 (93%) 821 (2%) <.001
CCS III/IV 16 (35%) 387 (0.8%) <.001
LVEF<35% 6 (13%) 114 (6%) <.001
HTN 38 (83%) 1321 (65%) .011
PHTN 29 (63%) 273 (13%) <.001
Dyslipidemia 32 (69%) 953 (47%) .003
PVD 25 (54%) 192 (9%) <.001
Arrhythmia 18 (39%) 259 (13%) <.001
COPD 18 (39%) 389 (19%) <.001
CVA 15 (33%) 206 (10%) <.001
Renal dysfunction 19 (41%) 291 (14%) <.001
Diabetes 14 (30%) 390 (19%) .062
Liver disease 5 (11%) 158 (8%) .453
Malignancy 5 (11%) 296 (15%) .445
Anemia 31 (67%) 200 (10%) <.001
PCI 11 (24%) 110 (5%) <.001
MI 19 (41%) 186 (9%) <.001
GI bleed 8 (17%) 138 (7%) .009
Remote smoker 19 (41%) 530 (26%) .022
Current smoker 3 (7%) 155 (8%) .800
Previous Sternotomy 17 (37%) 96 (5%) <.001
Creatinine 118 (105) 94 (53) .129
Hemoglobin 116 (15) 134 (16) <.001
Values expressed as mean (standard deviation) or number (%). AVR, Aortic valve
replacement; BSA, body surface area; CCS, Canadian Cardiovascular Society; COPD,
chronic obstructive pulmonary disease;CVA, cerebrovascular accident;HTN, hyperten-
sion; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New
York Heart Association classification; PCI, percutaneous coronary intervention;
PHTN, pulmonary hypertension;PVD, peripheral vascular disease;GI, gastrointestinal.
TABLE 7. Cause of 30-day mortality for matched and unmatched
transapical aortic valve implantation cases
Sex Age, y
Days
postoperative Cause of death
Matched TAVI
1 M 91 9 Pneumonia, sepsis, multiorgan failure
2 M 76 27 Pneumonia, sepsis, multiorgan failure
3 M 91 11 Aspiration pneumonia
4 M 87 11 Ischemic bowel
5 M 58 5 Liver cirrhosis, coagulopathy,
cardiopulmonary arrest, large
hemothorax post-chest tube insertion
6 F 78 Intraoperative Cardiopulmonary arrest before valve
deployment, heart failure
Unmatched TAVI
1 F 71 10 Ischemic bowel
2 F 82 Intraoperative Left coronary ostia obstruction by
native valve leaflet
3 M 78 3 Large pulmonary embolus
4 F 80 5 Sepsis, multiorgan failure
5 M 87 5 Cardiopulmonary arrest
TAVI, Transapical aortic valve implantation.
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our matching process, we included every patient who under-
went transapical AVI before May 2010. Thus, we are com-
paring a new procedure with a well-established approach,
which likely underestimates the true benefits of the new
procedure once the initial learning curve is overcome. In
this study, we saw that 50% of the perioperative mortalitiesTABLE 6. Early clinical outcomes formatched transapical aortic valve
implantation and conventional aortic valve replacement cases
TAVI (n ¼ 46) AVR (n ¼ 46) P value
30-d mortality 6 (13%) 4 (9%) .527
CVA 0 (0%) 2 (4%) –
Wound Infection 0 (0%) 0 (0%) –
Reoperation for bleeding 5 (11%) 2 (4%) .629
Postoperative LOS (d) 9 (7) 8 (7) .205
Number of patients (%) or median (interquartile range). TAVI, Transapical aortic
valve implantation; AVR, aortic valve replacement; CVA, Cerebrovascular accident;
LOS, length of stay.
The Journal of Thoracic and Cain the matched transapical AVI group were among the first
15 transapical AVI cases performed at our center. We antic-
ipate that there will be less of a learning curve in new trans-
apical programs, because mentoring can now be provided
by experienced, well-qualified surgeons.
Detailed exploration of causes of perioperative mortality
provides insight into potential areas of future improvement.
Among the patients undergoing transapical AVI, the major-
ity of deaths resulted from infection, multiorgan failure, and
exacerbation of preoperative comorbidities, including PVD,
liver cirrhosis, and renal dysfunction. This emphasizes the
importance of preoperative optimization of patients’ other
medical conditions, intensive perioperative care, and early,
aggressive treatment of complications.Study Limitations
Limitations of this study result mainly from the propen-
sity score model. First, as alluded to above, unmeasured
or unknown risk factors cannot be included in the propen-
sity score, although they would be accounted for if patientsTABLE 8. Early clinical outcomes for matched and unmatched
transapical aortic valve implantation cases
Matched TAVI
(n ¼ 46)
Unmatched TAVI
(n ¼ 46) P value
30-d mortality 6 (13%) 5 (11%) .064
CVA 0 (0%) 2 (4%) —
Wound infection 0 (0%) 0 (0%) —
Reoperation for bleeding 5 (11%) 7 (15%) <.001
Postoperative LOS (d) 9 (7) 8 (7) 1.000
Number of patients (%) or median (interquartile range). TAVI, Transapical aortic
valve implantation; CVA, cerebrovascular accident; LOS, length of stay.
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TABLE 9. Early clinical outcomes for matched and unmatched
conventional aortic valve replacement cases
Matched AVR
(n ¼ 46)
Unmatched AVR
(n ¼ 2042) P value
30-d mortality 4 (9%) 37 (2%) <.001
CVA 2 (4%) 26 (1%) .080
Wound infection 0 (0%) 10 (0.5%) —
Reoperation for bleeding 2 (4%) 153 (7%) .443
Postoperative LOS (d) 8 (3) 6 (4) 1.000
Number of patients (%) or median (interquartile range). AVR, Aortic valve replace-
ment; CVA, cerebrovascular accident; LOS, length of stay.
Acquired Cardiovascular Disease Higgins et al
A
C
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risk factors, such as concomitant coronary artery disease,
frailty, immobility, end-stage liver disease, and end-stage
lung disease, are often the reason to decline patients for con-
ventional AVR. However, many of these variables are not
collected in the Cardiac Services BC registry and thus could
not be included in the matching process. Second, including
too many variables in the propensity score will result in
none of the patients being matched, whereas using only
a small number of variables will produce results that are
not clinically meaningful. Consequently, we included only
those variables that were demonstrated to be statistically
significant in the decision to select a patient for transapical
AVI instead of conventional AVR. Because transapical AVI
is offered to extremely high-risk patients who previously
would have been denied any surgical intervention, it is
not possible to match the highest risk patients in a clinically
meaningful way. Despite these limitations, a propensity-
matched comparison of outcomes after these 2 aortic valve
procedures is the best available technique for analyzing
these observational data. However, a randomized clinical
trial would provide a more accurate comparison of the clin-
ical outcomes for these 2 groups.
Other limitations of this study include the retrospective
review of a prospectively maintained database and low
event rates resulting in a study potentially underpowered
to detect small differences that may be clinically meaning-
ful. Furthermore, future studies should include a comparison
of outcomes beyond the perioperative period.
CONCLUSIONS
Among patients who could be matched, preliminary re-
sults show no difference in 30-day mortality or in-hospitale52 The Journal of Thoracic and Cardiovascular Surgcomplication rates between propensity-matched transapical
AVI and conventional AVR cases. However, the lack of
study power and the limitations of propensity score match-
ing need to be considered when interpreting this finding. Fu-
ture studies should also explore outcomes beyond the
perioperative period.
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